|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0020924,
umls-concept:C0021469,
umls-concept:C0031727,
umls-concept:C0038215,
umls-concept:C0205549,
umls-concept:C0220781,
umls-concept:C0220825,
umls-concept:C0243077,
umls-concept:C1366876,
umls-concept:C1705633,
umls-concept:C1833235,
umls-concept:C1883254
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2001-5-16
|
|
pubmed:abstractText |
As a continuation of our work with 1,4,5 substituted imidazole inhibitors of p38alpha, we report a series of 1-(4-piperidinyl)-4-(4-fluorophenyl)-5-(2-phenoxy-4-pyrimidinyl) imidazoles related to 7. The compounds have IC50's for inhibition of p38alpha ranging from 6.0 to 650nM. Statistical analysis of the p38beta inhibitor potencies shows a correlation of IC50's with the electron donating strength of low molecular weight substituents.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
7
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1123-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Phenoxypyrimidine inhibitors of p38alpha kinase: synthesis and statistical evaluation of the p38 inhibitory potencies of a series of 1-(piperidin-4-yl)-4-(4-fluorophenyl)-5-(2-phenoxypyrimidin-4-yl) imidazoles.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry , GlaxoSmithKline Pharmaceuticals, King of Prussia, PA 19406, USA. jeffrey_c_boehm@sbphrd.com
|
|
pubmed:publicationType |
Journal Article
|
